Is MA Still Worth It?

Every MA plan board, every health insurer CFO, and every healthcare investor is running the same calculation in 2026. Medicare Advantage grew to over 55% of Medicare enrollment on the strength of zero-premium plans, rich supplemental benefits, aggressive broker distribution, and a coding-driven revenue model that generated returns exceeding those of any other insurance line of business. The 0.09% advance notice is the trigger for the current reassessment, but the question is structural. Can private insurers generate sustainable returns in MA when CMS is simultaneously compressing rates, tightening risk adjustment, excluding chart reviews, and signaling encounter-based RA?

The answer depends on who is asking. A national carrier with a 30% share of MA enrollment, a chart-review-dependent coding infrastructure, and a medical loss ratio above 89% faces a different calculus than a regional nonprofit with 4.5 stars, encounter-based documentation, and a 96-cent care delivery ratio. A payvider whose delivery system captures clinical volume regardless of insurance margin inhabits a different economic universe than a standalone insurer whose only MA revenue comes through capitation. The question is not whether MA is worth it in the abstract. It is whether the specific operating model a given plan has built can survive the rate and risk adjustment environment now taking shape, and if it cannot, what the alternative looks like.

The Financial Backdrop

#

The earnings picture across the five largest MA carriers tells a consistent story of margin pressure, but the strategic responses are diverging in ways that will reshape the competitive landscape over the next three years.

Humana posted a $796 million loss in Q4 2025, with its full-year MLR at 90.4%, unchanged from 2024 and within the company’s guidance window of 90.1% to 90.5%. Humana attributed the persistent MLR pressure to rising Part D enrollment alongside declining MA membership, since Part D carries a structurally higher MLR, compounded by investments in outcomes improvement and operational infrastructure. The company’s Star Ratings collapsed for 2025, with the share of Humana members in 4-star or above plans falling from 94% to 25%, a plunge that will cost the company quality bonus payments throughout 2026. Humana guided to adjusted EPS of at least $9.00 for 2026, well below the analyst consensus of $12.00, with the year-over-year decline attributed to the Star Ratings headwind net of mitigation. Humana filed a lawsuit challenging the 2025 Star Ratings, lost in district court in October 2025, and has appealed.

Despite the financial pressure, Humana made a strategic bet that diverged from every other major carrier. It maintained benefit generosity for 2026 while competitors cut, and gained approximately 1 million individual MA members during the 2026 annual enrollment period, a roughly 20% increase that could make Humana the largest MA insurer by year-end 2026, overtaking UnitedHealth. The strategy is a volume play: attract members now with competitive benefits, invest in CenterWell’s primary care platform (which saw 25% patient growth in 2025), and convert the membership base into a payvider model where clinical operations generate margin that insurance operations alone cannot. Whether the new members prove profitable or repeat the adverse selection pattern Humana experienced in prior growth cycles is the open question that investors are pricing with skepticism.

UnitedHealth projected its first revenue decline in over three decades for 2026, guiding to approximately $439 billion, a 2% contraction. The company forecast a loss of 1.3 to 1.4 million MA members as it executed what it called “targeted plan exits” in unprofitable counties and reduced benefits where margin could not sustain the prior year’s offerings. UnitedHealthcare CEO Tim Noel characterized the 0.09% rate proposal as something that does not reflect the reality of medical utilization and cost trends. UnitedHealth’s Q4 2025 MLR sat at 89.1%, and the company reported adjusted EPS of $2.11, in line with estimates but down roughly 70% from the same quarter in 2024. The company also disclosed a $799 million revenue hit from the Change Healthcare cyberattack.

UnitedHealth’s strategic response is margin-first: sacrifice volume, exit unprofitable geographies, and lean into Optum’s care delivery and data analytics businesses as offsets to insurance margin pressure. Optum Health employs or affiliates with tens of thousands of physicians, giving UnitedHealth partial payvider characteristics for a significant slice of its MA population. The company’s long-term bet is that Optum’s delivery system, pharmacy benefit management through Optum Rx, and data infrastructure through Optum Insight can generate earnings growth even if the UnitedHealthcare insurance segment contracts. Whether that bet works depends on Optum’s ability to manage care costs for the MA members UnitedHealth retains, which is a clinical operations question, not an insurance pricing question.

CVS Health faces a compounding challenge. Its Aetna MA business carries what analysts describe as disproportionate chart review exposure. Mizuho’s analysis flagged CVS/Aetna as the primary loser under the chart review exclusion, estimating that unlinked chart reviews touch an outsized share of Aetna’s MA enrollee population relative to competitors. The $7.2 billion chart review exclusion hits Aetna harder on a per-enrollee basis than it hits UnitedHealth or Humana. CVS’s strategic response was supposed to be the Signify Health and Oak Street Health acquisitions, designed to build payvider-adjacent capabilities: Signify for in-home health evaluations and risk assessment, Oak Street for value-based primary care delivery. But integration is ongoing, the acquisitions have not yet produced the cost structure transformation needed to offset MA margin compression, and CVS is simultaneously managing its retail pharmacy business through a period of reimbursement pressure and store closures. CVS shares fell 13% on the advance notice day, and the company faces the most challenging strategic position of the major MA carriers because it must execute a payvider transition while its existing MA economics are deteriorating faster than the transition can produce results.

Elevance and Cigna have lighter MA exposure relative to their total business than UnitedHealth, Humana, or CVS. That lighter exposure, once viewed as a growth gap that analysts pushed management to close, now looks like a defensive position. Elevance dropped approximately 13% on the advance notice day; Centene, with a Medicaid-heavy portfolio, fell more than 10%. Molina Healthcare announced a complete exit from the traditional MA market by 2027, a decision that reflects the arithmetic conclusion that MA margin at current rates does not justify the capital allocation for a company whose core competency is Medicaid managed care.

The utilization headwind compounds everything. Post-COVID utilization has not returned to pre-pandemic baselines in the way actuaries projected. Inpatient admissions, skilled nursing facility stays, and outpatient surgical volumes remain elevated relative to the trend lines plans used in their 2024 and 2025 bids. Supplemental benefit utilization has spiked as beneficiaries increasingly use the dental, vision, hearing, OTC, and transportation benefits that plans marketed aggressively to attract enrollment. Plans priced these benefits based on utilization assumptions derived from pre-expansion periods when fewer beneficiaries knew they had the benefits or how to access them. The gap between assumed and actual supplemental benefit utilization is a persistent MLR drag that operates independently of the rate environment. NAIC data showed MA medical loss ratios rising from 85.6% in Q2 2024 to 86.8% in Q2 2025, with average gross profit margins essentially flat at $194 per member per month, still higher than any other insurance segment but on a negative trajectory that the 0.09% rate environment will accelerate.

The Revenue Compression Stack

#

The rate environment and the risk adjustment tightening hit plan revenue from two directions simultaneously, and their interaction is multiplicative rather than additive.

On the rate side, the 0.09% advance notice proposes benchmark growth that is effectively flat (MCR-02.01). The effective growth rate of 4.97% is largely offset by the chart review exclusion, risk adjustment model recalibration, and normalization adjustments. The $700 million in net additional payments across the entire MA program compares to over $25 billion in CY 2026.

On the risk adjustment side, three mechanisms compress simultaneously. V28’s full phase-in reduced the coefficients for many commonly coded conditions and eliminated approximately 2,294 ICD-10 codes from payment status (MCR-02.03). The chart review exclusion removes an estimated $7.2 billion by excluding unlinked retrospective diagnoses from risk score calculation (MCR-02.02). The coding pattern adjustment at 5.9% continues to reduce payments for aggregate coding intensity differential. Each mechanism addresses a different dimension of the coding-to-payment relationship, and their combined effect is larger than any single mechanism alone.

Plans translate the rate environment into bids submitted by June 1. The bid represents what the plan estimates it will cost to cover the Part A and Part B benefit package for a beneficiary of average health status. If the bid falls below the county benchmark, the plan receives its bid plus a rebate equal to a percentage of the bid-benchmark difference. That percentage depends on Star Rating: 4-star and above plans receive 65% or 70% of the difference; lower-rated plans receive 50%. Plans use the rebate to fund supplemental benefits, buy down premiums, and cover administrative costs and margin.

The rebate is the funding mechanism for everything that differentiates MA from Original Medicare. When benchmarks barely grow and risk-adjusted revenue declines, the gap between bid and benchmark narrows. When the gap narrows, the rebate shrinks. When the rebate shrinks, the supplemental benefit funding contracts. A plan operating in a county with a $1,100 monthly benchmark, bidding at $1,000, would have generated a $100 gap and a $65 to $70 rebate per member per month under the prior environment. Under the 0.09% rate with chart review exclusion, the benchmark barely increases while the plan’s costs rise, forcing the bid higher. If the bid rises to $1,060, the gap shrinks to $40, the rebate drops to $26 to $28, and the $40 per-member-per-month reduction in rebate funding is the supplemental benefit cut the beneficiary experiences in January 2027 (MCR-04.02).

The Market Exit Calculus

#

County-level exit becomes rational when the benchmark, net of the plan’s bid, quality bonus, and administrative costs, produces a negative margin. The variables are county-specific: benchmark level, Star Rating and QBP eligibility, local MLR, chart review dependence, and the administrative cost of maintaining network adequacy.

Plans exit first at the intersection of multiple unfavorable variables. National carriers with thin margins in peripheral markets where enrollment is too small to justify fixed network management costs. Plans below 4 stars that do not receive the 5% quality bonus payment and therefore operate with a structurally lower benchmark. Plans in low-benchmark rural counties where the absolute benchmark level is insufficient to cover the cost of care at any reasonable MLR. A plan with 3.5 stars in a rural county with a $900 monthly benchmark has almost no path to profitability: no QBP, minimal rebate room, high per-member administrative cost, and limited provider network options.

UnitedHealth has already signaled further exits beyond its 2026 contraction. The 2026 AEP saw seven states experience MA enrollment declines, including complete market exit in Vermont. UnitedHealth and Aetna significantly retreated from Maryland. HealthScape’s survey found plan leaders increasingly acknowledging that structural changes to benchmark methodology are necessary for MA sustainability, an admission that current economics do not work for significant portions of the market.

For beneficiaries, plan exit triggers a coverage transition that can be financially devastating. Beneficiaries who enrolled in MA years ago and allowed their Medigap open enrollment period to lapse face medical underwriting if they attempt to purchase a Medigap policy in most states. A 75-year-old with diabetes, hypertension, and cardiac history who has been in MA for eight years may find Medigap policies either unavailable or priced beyond affordability. BMA research found 2.9 million enrollees experienced forced disenrollments in CY 2026 due to plan terminations. The Medigap underwriting barrier converts a plan’s financial decision into a beneficiary’s coverage crisis (MCR-00.03).

The MA Penetration Paradox

#

More than 55% of Medicare beneficiaries are now enrolled in MA, covering approximately 35 million people. And the plans serving them are under the most acute financial pressure the program has experienced since the ACA-era benchmark reductions.

The paradox is that enrollment growth does not resolve the profitability problem. It compounds it. More members at below-cost rates means more aggregate losses. The fixed costs of network management, compliance infrastructure, and administration spread across a larger base, but the variable cost of medical care for each additional member exceeds the revenue that member generates at current rates. Humana’s 2026 enrollment surge illustrates the dynamic: a million new members and disappointing earnings guidance, because new members arrive with utilization patterns the plan must manage at rates that do not cover the cost.

MA reached 55% penetration through a specific growth engine. Zero-premium plans funded by rebates generated from chart-review-enhanced risk scores and quality bonus payments, distributed through broker channels incentivized by generous commissions. Each element is now under pressure from a different direction. Chart review revenue is being excluded. Star Ratings are volatile. Broker compensation is being contested in court, investigated by the Senate Finance Committee, and prosecuted by DOJ. Supplemental benefit utilization exceeds what plans priced for. The growth-first strategy was premised on a rate and regulatory environment that no longer exists.

The AEP 2026 data confirms the shift. MA enrollment grew by only 0.3% during the enrollment period, less than one-fourth of the prior year’s increase and the slowest growth in over a decade. The growth slowdown reflects plan retreat: carriers cut benefits, exited counties, and reduced marketing spend because the economics of adding members deteriorated.

What Sustainable MA Looks Like

#

The MA model that grew to 55% penetration is not the model that survives the current rate environment. What replaces it has three dimensions.

Premium recalibration. MA has been marketed as a $0-premium product for over a decade. CMS data showed average premiums declining to $14.00 per month for 2026, with BMA estimating 59% of plans carrying a $0 premium. But plans in lower-benchmark counties without QBP are increasingly unable to sustain $0 premiums without accepting negative margins. The premium sensitivity question is how much increase beneficiaries absorb before switching. A beneficiary paying $0 who learns their plan will cost $45 per month next year will recalculate. If their medications are generic, their providers accept assignment, and they can obtain Medigap, TM may deliver better total value. If they have chronic conditions and Medigap is medically underwritten, they stay in MA because they have no alternative. The premium recalibration will sort MA into beneficiaries who choose it for value and beneficiaries who remain because they are locked in.

Benefit right-sizing. The supplemental benefit pullback is underway and will accelerate for CY 2027 (MCR-04.02). HealthScape found nearly 70% of plan leaders expecting less rich benefits, with sharpest degradation in non-core supplementals. The question is whether MA remains attractive without the extras. The core medical proposition, coordinated care, managed networks, lower cost-sharing, integrated pharmacy, is real and measurable. MA enrollees have lower hospital and ED use and higher preventive care rates. But these advantages are less visible than a dental benefit or OTC card. Plans must learn to market clinical value rather than supplemental benefit volume, which is a harder consumer proposition.

The payvider pathway. Plans that own their delivery system have a structurally different cost base. When insurer and provider share a balance sheet, MLR is an internal transfer. The cost of care is managed through clinical operations, not claims adjudication. The delivery system captures volume generating revenue independent of insurance margin, meaning the organization sustains MA operations through insurance-side margin compression that would force a standalone insurer to exit.

Kaiser, UPMC, Geisinger, and CareOregon are the existence proofs. Kaiser’s integrated model has operated through multiple rate cycles without the financial distress the national carriers are experiencing, because its cost structure is built around clinical delivery efficiency. UPMC and Geisinger demonstrate the model works across different market demographics.

The national carriers are attempting to build payvider capabilities through acquisition. UnitedHealth’s Optum Health, Humana’s CenterWell, CVS’s Oak Street. But acquisition-based strategies face integration challenges organic models do not. Optum physicians may not be clinically integrated with UnitedHealthcare’s insurance operations. CenterWell clinics may function as standalone cost centers. Oak Street’s model may not survive integration into CVS’s conglomerate. Whether these acquisitions produce genuine integration or remain bolt-on assets will determine whether the national carriers can replicate what Kaiser built over decades (MCR-05.02).

The ACO-to-payvider pipeline represents the next generation. Large physician-led ACOs in MSSP and ACO REACH are accumulating risk management experience, clinical data infrastructure, and population health capabilities that position them to take on full insurance risk. An ACO managing total cost of care for 50,000 attributed beneficiaries under two-sided risk is performing many of the same functions an MA plan performs, without the insurance license. The step from ACO to provider-sponsored MA plan is organizational and regulatory rather than conceptual. Whether the current ACO cohort takes that step depends on the rate environment, access to capital, and whether the regulatory pathway supports the transition (MCR-05.03, MCR-05.04).

MA is not dying. But the version of MA that grew to 55% penetration is no longer viable. What replaces it is leaner, more clinical, and more integrated. This series examines each dimension of that replacement.

Related Reading

#

MCR-02_01 The 0.09% Shock: What CMS Actually Proposed for 2027 MCR-05_02 Becoming a Payvider: The Strategic Case for Provider Plan Ownership MCR-12_01 The MA Plan Landscape Under Pressure: UnitedHealth, Humana, CVS/Aetna, Elevance, and the Regional Plans MCR-00_01 The Trust Fund Clock